Ms. magazine  -- more than a magazine a movement

SIGN UP FOR MS. DIGEST, JOBS, NEWS AND ALERTS

FEMINIST WIRE NEWSBRIEFS

ABOUT
SEE CURRENT ISSUE
SHOP MS. STORE
MS. IN THE CLASSROOM
FEMINIST DAILY WIRE
FEMINIST RESOURCES
PRESS
JOBS AT MS.
READ BACK ISSUES
CONTACT
RSS (XML)
 
feminist wire | daily newsbriefs

August-16-10

FDA Approves 5-Day Emergency Contraceptive

The Food and Drug Administration (FDA) has approved a new emergency contraceptive, Ella or ulipristal acetate, which is effective at preventing pregnancy up to five days after contraceptive failure or unprotected sexual intercourse. In June, a panel of FDA expert medical advisors unanimously agreed that it is safe and effective in preventing the release of an egg. The drug inhibits or delays ovulation by diminishing the effects of progesterone, according to theFDA release.

Ella will be available by prescription only, according to the Los Angeles Times.

According to the New York Times, Ella is more effective than Plan B, the "morning-after" pill available over the counter to women over the age of 17 in the United States. Plan B is only effective three days after contraceptive failure or unprotected sex. Side effects of Ella are similar to those of Plan B, including headache, nausea, abdominal pain, pain/discomfort during menstruation (dysmenorrhea), fatigue, and dizziness, according to WebMD Health News.

The drug, under the name EllaOne, is made by French company HRA Pharma. It is available with a prescription in Europe and is currently approved in 22 countries. Watson Pharmaceuticals Inc. will distribute Ella in the United States.

Anti-choice advocates argue that EllaOne is akin to mifepristone, which terminates existing pregnancies. According to Reuters, supporters of EllaOne agree that the drug is chemically similar to mifepristone, but one dose will not interfere with existing pregnancies. "There's just no evidence that it causes abortion," said Dr. Paul Fine, a Baylor College of Medicine professor and the medical director for Planned Parenthood in Houston and Southeast Texas.

Planned Parenthood has commended the FDA's decision. Planned Parenthood President Cecile Richards said, "Every woman deserves every option available to prevent an unplanned pregnancy, and there are many reasons why a woman may face the risk of unintended pregnancy, from failure or improper use of birth control to sexual assault," in a statement. "The FDA's approval of this new form of emergency contraception gives women one more option."

Media Resources: FDA Release; Feminist Newswire 6/16/10, 6/18/10; Los Angeles Times 8/13/10; New York Times 8/13/10; WebMD Health News 8/13/10; Planned Parenthood Press Release 8/13/10; Reuters 6/15/10


© Feminist Majority Foundation, publisher of Ms. magazine

If you liked this story, consider making a tax-deductible donation to support Ms. magazine.

 

 

Send to a Friend
Their
Your
Comments
(optional)


More Feminist News

5/27/2015 California Passes Reproductive FACT Act - The California State Assembly passed the Reproductive Freedom, Accountability, Comprehensive Care and Transparency (FACT) Act yesterday. AB 775, or the FACT Act, passed 48-25 in a vote, and requires that unlicensed facilities in California that provide pregnancy-related services disclose that they are not licensed medical providers. . . .
 
5/26/2015 Ireland Votes Overwhelmingly to Legalize Same-Sex Marriage - Over the weekend, the people of Ireland voted overwhelmingly to pass a national referendum legalizing same-sex marriage. Ireland became the first country in the world to pass marriage equality through popular vote on Friday. . . .
 
5/26/2015 Maryland Governor Will Not Veto LGBT Rights Bills - Maryland Governor Larry Hogan (R) has announced that he will not veto two pieces of legislation protecting LGBT rights passed by the state legislature in March, meaning they will soon become law. The Maryland General Assembly passed SB 743 / HB 862 and SB 416 / HB 838 by wide margins and with bipartisan support on March 24, after which both were sent to the Governor's desk. . . .